Published in World J Gastroenterol on July 28, 2010
Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-β2. Neoplasia (2011) 1.09
Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells. PLoS One (2015) 0.83
Diagnostic accuracy of serum squamous cell carcinoma antigen and squamous cell carcinoma antigen-immunoglobulin M for hepatocellular carcinoma: A meta-analysis. Mol Clin Oncol (2015) 0.76
Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology (2007) 26.78
Hepatocellular carcinoma. Lancet (2003) 22.54
Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta (2003) 7.85
Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology (2003) 2.90
Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun (2003) 2.78
Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res (2005) 2.68
Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res (2004) 2.34
Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol (2000) 2.18
hSulf1 Sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. Gastroenterology (2004) 1.95
Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology (2008) 1.87
Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc Natl Acad Sci U S A (2001) 1.84
Relation of enhanced secretion of active matrix metalloproteinases with tumor spread in human hepatocellular carcinoma. Gastroenterology (1997) 1.60
Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer (2003) 1.54
The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol (2005) 1.52
Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut (2001) 1.46
Expression of p53 gene in 184 unifocal hepatocellular carcinomas: association with tumor growth and invasiveness. Cancer Res (1993) 1.45
Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation. Oncogene (2007) 1.44
Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. Cancer Res (2008) 1.35
Deletions of chromosome 13q, mutations in Retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res (1994) 1.34
Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer Sci (2003) 1.34
Detection of hypermethylation of the p16(INK4A) gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus. Gut (2001) 1.30
OCI-5/rat glypican-3 binds to fibroblast growth factor-2 but not to insulin-like growth factor-2. J Biol Chem (1997) 1.28
Frequent epigenetic inactivation of SFRP genes in hepatocellular carcinoma. J Gastroenterol (2008) 1.25
Transcriptional silencing of hedgehog-interacting protein by CpG hypermethylation and chromatic structure in human gastrointestinal cancer. J Pathol (2007) 1.24
Ectopic activity of fibroblast growth factor receptor 1 in hepatocytes accelerates hepatocarcinogenesis by driving proliferation and vascular endothelial growth factor-induced angiogenesis. Cancer Res (2006) 1.07
Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions. Arch Pathol Lab Med (2008) 1.06
Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway. Carcinogenesis (2008) 1.02
Overexpression of the receptor tyrosine kinase EphA4 in human gastric cancers. World J Gastroenterol (2008) 1.01
Glypican-3 regulates migration, adhesion and actin cytoskeleton organization in mammary tumor cells through Wnt signaling modulation. Breast Cancer Res Treat (2008) 0.97
Glypican-3 as a serum marker for hepatocellular carcinoma. Cancer Res (2005) 0.94
Inhibition of invasion and metastasis by glypican-3 in a syngeneic breast cancer model. Breast Cancer Res Treat (2003) 0.91
Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas. Mol Cancer Ther (2008) 0.86
Matrix metalloproteinase-9 associated with heparan sulphate chains of GPI-anchored cell surface proteoglycans mediates motility of murine colon adenocarcinoma cells. J Biochem (2008) 0.84
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet (2004) 7.78
Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature (2003) 4.80
Retracted A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet (2009) 3.88
Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res (2008) 3.81
Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology (2003) 3.52
Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet (2007) 3.39
NAC transcription factors, NST1 and NST3, are key regulators of the formation of secondary walls in woody tissues of Arabidopsis. Plant Cell (2007) 2.85
A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. Cancer Cell (2010) 2.78
Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation (2008) 2.72
BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene (2003) 2.56
Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology (2003) 2.53
Upregulation of miR-196a and HOTAIR drive malignant character in gastrointestinal stromal tumors. Cancer Res (2012) 2.45
Prediction of postoperative visual outcome based on hole configuration by optical coherence tomography in eyes with idiopathic macular holes. Am J Ophthalmol (2004) 2.35
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet (2006) 2.33
Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med (Maywood) (2006) 2.33
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis (2007) 2.27
A genome-wide association study identifies three new susceptibility loci for ulcerative colitis in the Japanese population. Nat Genet (2009) 2.26
A DNA methylation fingerprint of 1628 human samples. Genome Res (2011) 2.16
A novel pit pattern identifies the precursor of colorectal cancer derived from sessile serrated adenoma. Am J Gastroenterol (2012) 2.06
Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene (2003) 1.91
A new conceptualization for Mikulicz's disease as an IgG4-related plasmacytic disease. Mod Rheumatol (2006) 1.91
Spatial regulation of VEGF receptor endocytosis in angiogenesis. Nat Cell Biol (2013) 1.89
c-kit gene mutation at exon 17 or 13 is very rare in sporadic gastrointestinal stromal tumors. J Gastroenterol Hepatol (2003) 1.84
DNA hypermethylation contributes to incomplete synthesis of carbohydrate determinants in gastrointestinal cancer. Gastroenterology (2008) 1.83
Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene (2005) 1.82
Endoscopic submucosal dissection is superior to conventional endoscopic resection as a curative treatment for early squamous cell carcinoma of the esophagus (with video). Gastrointest Endosc (2010) 1.82
Clinical and pathological characteristics of Mikulicz's disease (IgG4-related plasmacytic exocrinopathy). Autoimmun Rev (2004) 1.80
Disturbed gastrointestinal motility and decreased interstitial cells of Cajal in diabetic db/db mice. J Gastroenterol Hepatol (2008) 1.74
Effectiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-eluting stent restenosis. JACC Cardiovasc Interv (2011) 1.70
Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum Mol Genet (2004) 1.66
Treatment of relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: the Nagasaki Transplant Group experience. Blood (2012) 1.65
Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood (2003) 1.65
Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis (2003) 1.64
Measurement of Pseudomonas aeruginosa multidrug efflux pumps by quantitative real-time polymerase chain reaction. FEMS Microbiol Lett (2005) 1.63
BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene (2005) 1.62
Risk of malignancies in IgG4-related disease. Mod Rheumatol (2011) 1.61
Association of Mycoplasma pneumoniae infection with coronary artery disease and its interaction with chlamydial infection. Atherosclerosis (2004) 1.60
Pathologic features of mucin-producing bile duct tumors: two histopathologic categories as counterparts of pancreatic intraductal papillary-mucinous neoplasms. Am J Surg Pathol (2004) 1.59
Smad-dependent GADD45beta expression mediates delayed activation of p38 MAP kinase by TGF-beta. EMBO J (2002) 1.59
Aberrant methylation and silencing of the BNIP3 gene in colorectal and gastric cancer. Clin Cancer Res (2005) 1.58
Epigenetic inactivation of CHFR in human tumors. Proc Natl Acad Sci U S A (2003) 1.57
Intractable colitis associated with chronic granulomatous disease. J Med Microbiol (2006) 1.56
Epidermal growth factor inhibits the growth of TE8 esophageal cancer cells through the activation of STAT1. J Gastroenterol (2002) 1.54
New classification of pancreatic intraductal papillary-mucinous tumour by mucin expression: its relationship with potential for malignancy. J Pathol (2002) 1.54
The expression of matrix metalloproteinase matrilysin indicates the degree of inflammation in ulcerative colitis. J Gastroenterol (2003) 1.53
Frequent epigenetic inactivation of DICKKOPF family genes in human gastrointestinal tumors. Carcinogenesis (2007) 1.52
Broadening of CD8+ cell responses in vaccine-based simian immunodeficiency virus controllers. AIDS (2010) 1.52
Methylation-associated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defect. Carcinogenesis (2010) 1.52
Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer (2003) 1.51
The p53 family member genes are involved in the Notch signal pathway. J Biol Chem (2001) 1.50
Comparison of green tea intake in Japanese patients with and without angiographic coronary artery disease. Am J Cardiol (2002) 1.49
Patients' skin dose during percutaneous coronary intervention for chronic total occlusion. Catheter Cardiovasc Interv (2008) 1.49
Seven-year clinical outcomes of unprotected left main coronary artery stenting with drug-eluting stent and bare-metal stent. Circ J (2013) 1.48
MR imaging of urinary bladder cancer for T-staging: a review and a pictorial essay of diffusion-weighted imaging. J Magn Reson Imaging (2013) 1.47
MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma. Clin Cancer Res (2006) 1.46
Basic fibroblast growth factor promotes the trans-differentiation of mouse bone marrow cells into hepatic lineage cells via multiple liver-enriched transcription factors. J Hepatol (2004) 1.45
Glycosaminoglycan modification of neuropilin-1 modulates VEGFR2 signaling. EMBO J (2006) 1.45
MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type. Hepatology (2004) 1.43
Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J (2009) 1.41
A decreased number of c- kit-expressing cells in a patient with afferent loop syndrome. J Gastroenterol (2003) 1.41
Usefulness of narrow-band imaging endoscopy for diagnosis of Barrett's esophagus. J Gastroenterol (2004) 1.40
Genome-wide profiling of chromatin signatures reveals epigenetic regulation of MicroRNA genes in colorectal cancer. Cancer Res (2011) 1.40
Tophaceous gout in the cervical spine. Intern Med (2012) 1.40
Classification of Barrett's epithelium by magnifying endoscopy. Gastrointest Endosc (2002) 1.40
Gag-specific cytotoxic T-lymphocyte-based control of primary simian immunodeficiency virus replication in a vaccine trial. J Virol (2008) 1.38
Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus. Cancer (2006) 1.37
IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype. Carcinogenesis (2009) 1.34